Skip to main content
. 2020 Nov 17;64(12):e00731-20. doi: 10.1128/AAC.00731-20

FIG 4.

FIG 4

ASPECT-NP study design. ACM, all-cause mortality; CE, clinically evaluable; C/T, ceftolozane-tazobactam; CLCR, creatinine clearance; EOT, end of treatment; ITT, intention-to-treat; MEM, meropenem; mITT, microbiological intention-to-treat; q8h, every 8 h; TOC, test of cure; VABP, ventilator-associated bacterial pneumonia; vHABP, ventilated hospital-acquired bacterial pneumonia.